Category Filter
- Advanced Imaging
- Autism Spectrum Mandate
- Behavioral Health
- Chronic Condition Management
- Genetic Testing
- HelpScript Program
- Hemophilia Drugs
- Medical Policies
- Pre-Service Review (Precertification/Predetermination)
- Provider-Administered Drug Policies
- Radiation Therapy
- Self-Administered Drug Policies
- Transgender Services
Asset Publisher
Draft Provider-Administered Drug Policies
Draft provider-administered drug policies are listed below. If there are no policies listed, it means there are currently no policies in draft status.
The drugs below require that a member’s medical condition meets the policy requirements prior to being given (precertification) unless otherwise specified. Providers must submit a request for pre-service review in order to be approved. If the provider does not receive approval for precertification, the plan will pay no benefits.
Precertification is required for these provider-administered drugs when administered in a provider’s office, outpatient facility or home health setting. Precertification does not apply to inpatient hospital claims at this time. Exceptions to this include: Luxturna, Kymriah and Yescarta, which require a precertification for any place of treatment.
Members can request a copy of a full drug policy by calling the Customer Service number on their ID card.
Comment on Draft Drug Policies
Participating providers are invited to submit for consideration scientific, evidence-based information, professional consensus opinions, and other information supported by medical literature relevant to our draft policies.
We accept comments for 45 days from the posting date listed on the draft policy.
Make sure your voice is heard by providing feedback directly to us:
- Complete our online policy feedback form
- Send comments with supporting documentation by mail or fax
Credence Blue Cross and Blue Shield Service Center
Attn: Pharmacy Department
P.O. Box 10447
Birmingham, AL 35202
Fax: 205-220-9576
Draft Provider-Administered Drug Policies
Draft policies are listed below. If there are no policies listed, it means there are currently no policies in draft status.
Note: Coverage is subject to member's specific benefits. Group specific policies will supersede these policies when applicable. Please refer to member's benefit plan.
Comment on Draft Drug Policies
Participating providers are invited to submit for consideration scientific, evidence-based information, professional consensus opinions and other information supported by medical literature relevant to draft policies.
Comments are accepted for 45 days from the posting date listed on the draft policy.
Make sure your voice is heard by providing feedback directly to us:
-
Complete our medical policy feedback form, or
-
Send comments by mail or fax to:
Birmingham Service Center
Attn: Health Management — Medical Policy
P.O. Box 10527
Birmingham, AL 35202
Fax: 205-220-0878